The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kurts, C.
Right arrow Articles by Brocker, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurts, C.
Right arrow Articles by Brocker, T.
The Journal of Immunology, 2001, 166: 1439-1442.
Copyright © 2001 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Dendritic Cells Are Sufficient to Cross-Present Self-Antigens to CD8 T Cells In Vivo1

Christian Kurts2,*,§, Michael Cannarile{dagger},{ddagger}, Ina Klebba§ and Thomas Brocker3,{dagger},{ddagger}

* Department of Nephrology and Immunology, University of Aachen, Aachen, Germany; {dagger} Institute for Immunology, Ludwig-Maximilians-Universität München, München, Germany; {ddagger} Max Planck Institute for Immunobiology, Freiburg, Germany; and § Medizinische Hochschule, Hannover, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
The mechanism of cross-presentation enables professional APCs to induce CD8 T cell-mediated immune responses against exogenous Ags. Through this mechanism, APCs can induce either immunity against infectious pathogens or tolerance against self-Ag residing in extralymphatic locations. An unanswered question in this field concerns the identity of the cross-presenting APC. All major classes of professional APCs, particularly dendritic cells, macrophages, and B cells, have previously been shown to be able to cross-present Ags in vitro. In the present study, we have created transgenic mice where MHC class I expression is driven selectively in dendritic cells and provide direct in vivo evidence that dendritic cells are sufficient to cross-present exogenous self-Ags and induce Ag-specific cell division of CD8-positive T cells.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
CD8 T cells are important immune mediators against malignancies and intracellular pathogens such as viruses. These cells recognize Ag presented by MHC class I molecules, which generally only present protein Ags synthesized within the presenting cell (1, 2). This Ag presentation pathway is known as the endogenous pathway, in contrast to the MHC class II-restricted pathway, which presents exogenous (extracellular) Ags to CD4 T cells. However, recent studies have demonstrated presentation of exogenous Ags also to CD8 T cells in vitro (3). Such "cross-presentation" has now been observed in many tolerogenic as well as immunogenic responses in vivo (3, 4, 5, 6), albeit its actual contribution to the functioning of the immune system remains controversial and seems to be Ag-dose dependent (7). Theoretically, this mechanism could enable professional APCs to induce CD8-mediated immune responses against viral, tumor, and self-Ag from nonlymphatic tissues, which lie outside the migration pathways of naive T cells. Thus, it may prevent viruses that do not infect professional APC from escaping immune surveillance (8), allow antitumor responses against nonlymphatic malignancies (4), and induce peripheral tolerance against nonlymphoid self-Ags (5).

After several reports that dendritic cells (DC)4 play a major role in processing and presenting peptides from dying cells to CD8 T cells (9, 10), it has been speculated that this APC type might be the principal cross-presenting cell (11). In vitro work has demonstrated that, depending on culture conditions, all major types of APCs, namely DC, macrophages, and B cells, are able to cross-present exogenous Ags (3, 9, 12, 13, 14). Recent in vitro findings also indicated that DC are more potent in cross-presenting exogenous Ag to CD8 T cells than macrophages or B cells (9, 15, 16). However, it is unknown which type of APC is responsible for in vivo cross-presentation. Therefore, we have used an in vivo approach employing the well-established rat insulin promotor (RIP)-membrane-bound OVA (mOVA)-transgenic mice, to identify the cross-presenting APC. In these animals, where the model self-Ag OVA is expressed under the control of the RIP, OVA expression can be detected in the pancreatic {beta} cells and proximal kidney (17). Bone marrow-derived APCs in the draining pancreatic and kidney lymph node constitutively cross-present nonlymphatic tissue-derived OVA. When OVA-specific transgenic CD8 T cells (OT-I cells) are injected into these mice, the T cells are activated and proliferate exclusively in these draining lymph nodes. By generating mice in which only CD11c+ DC can activate OT-I cells, we demonstrate that dendritic cells are sufficient to cross-present self-Ags in vivo.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Generation of the transgenic construct and mice

The cDNA encoding mouse {beta}2-microglobulin ({beta}2m) was amplified from total spleen cDNA of C57BL/6 mice using the oligonucleotides 5'-TCAGCATGGCTCGCTCGGTGACC-3' and 5'-ATGCTTGATCACATGTCTCGATC-3'. This PCR product was ligated into the blunt ended EcoRI site of the previously described vector CD11c-pDOI-5 (18). The orientation and integrity of the {beta}2m-cDNA was controlled by DNA sequence analysis. The linearized transgenic construct, devoid of vector sequences, was microinjected into the pronuclei of fertilized oocytes from (BDF1xBDF1) F1 mice, and transgenic offspring were subsequently identified by Southern blotting. We obtained four different founders with varying copy numbers and a similar transgene expression pattern. The founder line with ~20 transgene copies was bred for six generations to C57BL/6 mice and then for another four generations to {beta}2m-deficient animals (19), which had themselves been backcrossed for 11 generations to C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME). We will refer to these animals in this study as CD11c-MHCI mice. OT-I and RIP-mOVA.bm1-transgenic mice have been described previously (5).

All mice were bred and maintained at the animal facilities of the Medizinische Hochschule Hannover, the Max Planck Institute of Immunobiology, Freiburg (under special pathogen-free conditions) and the Institute for Immunology, University of Munich.

Bone marrow chimeras

As described previously (17), 8- to 12-wk-old RIP-mOVA.bm1 mice were lethally irradiated with 900 rad. Approximately 12 h later, they received i.v. 5 x 106 bone marrow cells, which were depleted of T cells by anti-Thy-1 (T24.1; a kind gift of J. Kirberg, Basel Institute for Immunology, Basel, Switzerland) and rabbit complement (Cedarlane, Hornby, Ontario, Canada) treatment. As bone marrow donors, we used either C57BL/6 mice, CD11c-MHCI mice, or transgene-negative littermates (MHCI-/-).

Adoptive transfer and FACS analysis

Preparation, CFSE labeling, and adoptive transfer of OT-I cells were conducted as described previously (5). PE-conjugated anti-CD8 (YTS 169.4) was obtained from Caltag (San Francisco, CA). All other Abs used in this study were purchased from BD PharMingen (San Diego, CA). With these mAbs, flow cytometry was performed on a FACSCalibur or a FACScan (BD Biosciences, Mountain View, CA) instrument. Single-cell preparation, staining, and FACS analysis were done according to standard procedures. Dead cells were excluded by propidium iodide staining. To analyze DC, organs of different mice were digested twice with collagenase (CLSPA; Worthington Biochemical, Freehold, NJ) for 30 min at 37°C as described previously (18). Cells were then recovered by centrifugation at 300 x g for 5 min, washed twice, and used for FACS analysis.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
Generation of mice expressing MHC class I on DC (CD11c-class I mice)

To express MHC class I selectively on DC, we used a 5-kb fragment containing the promoter region of mouse CD11c (see Material and Methods). This DC-specific promoter has been described previously to drive transgene expression selectively in DC in vivo (18, 20, 21, 22). We cloned cDNA encoding mouse {beta}2m into the expression cassette of this vector and obtained four different transgenic founder lines after transgene injection. These animals were backcrossed into the {beta}2m-deficient C57BL/6 background (see Materials and Methods and Ref. 19), and transgene expression was monitored using MHC class I Kb-specific mAb AF6-88.5. Thereafter, these mice are referred to as CD11c-MHCI.

Expression pattern of the {beta}2m transgene in peripheral lymphoid organs

Two different mouse strains were used as controls. Transgene-negative littermates of CD11c-MHCI mice were negative controls, because these animals correspond to normal MHC class I-deficient animals (19). They are devoid of {beta}2m expression in all organs and are referred to as MHCI-/- in this study. The positive control mice were C57BL/6 mice, which were termed MHCI+/+. A representative FACS analysis of spleen and lymph nodes of these mice is shown in Fig. 1Go. MHCI+/+ mice expressed MHC class I Kb in lymph nodes and spleen on both B220-positive B cells and on B220-negative non-B cells (Fig. 1Go, MHCI+/+). In contrast, MHCI-/- animals and CD11c-MHCI mice did not show detectable MHC class I expression on either cell population (Fig. 1Go, CD11c-MHCI, MHCI-/-).



View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 1. Expression of the CD11c-{beta}2m transgene does not lead to detectable MHC class I Kb expression on lymphocytes from transgenic mice. Single-cell suspensions of lymph nodes (left) and spleens (right) of MHCI+/+, CD11c-MHCI, and MHCI-/- mice were obtained by teasing organs through a mesh. Cells were stained with mAbs specific for B220 (PE) and MHC class I Kb (FITC), respectively. Shown are all cells with the gates set on live cells only. The numbers shown in the right top corner represent the percentage of Kb-positive cells relative to the vertical marker in each dot plot.

 
We next performed flow cytometric analysis on freshly isolated spleen cells (Fig. 2Go) from the different strains, first gating on cells with relatively high forward scatter and intermediate side scatter signals (data not shown). When these cells where stained for CD11c and CD11b, we identified three major populations as described previously (23, 24, 25). These discrete populations were further analyzed for their MHC class II I-Ab and MHC class I Kb expression. As expected, none of the cell populations from MHCI-/- mice showed MHC class I Kb expression (Fig. 2Go, right, all histograms, thin black line) above background autofluorescence levels (data not shown). Cells that are CD11c+CD11b- (population 1, Fig. 2Go) have been reported to coexpress CD8{alpha} and DEC205, surface markers that are typical for lymphoid-derived DC (24). In this lymphoid-related DC subpopulation, MHC class I Kb expression was found to be identical in DC from MHCI+/+ and CD11c-MHCI mice (Fig. 2Go, right, histogram 1). The CD11c+CD11b+ DC-population (population 2, Fig. 2Go) is thought to represent mature myeloid-related DC and has been shown to be negative for CD8{alpha} and DEC205 (24, 25). In this population, MHCI+/+ and CD11c-MHCI DC expressed similar levels of Kb, while DC from MHCI-/- animals were Kb negative (Fig. 2Go, histogram 2). As expected for DC, the CD11c+CD11b- and CD11c+CD11b+ populations expressed high levels of MHC class II I-Ab (Fig. 2Go, left, histograms 1 and 2). In the majority of the third population (CD11c-CD11b+), we observed MHC class I transgene expression at levels only slightly above the background levels of MHCI-/- mice (data not shown). When this population was divided into three subpopulations according to their relative CD11c-expression (populations 3–5, Fig. 2Go), we found the expected positive correlation between transgene and CD11c expression (Fig. 2Go, histograms 3–5). Furthermore, as compared with the DC-typical high MHC class II expression observed in the CD11c+ populations (Fig. 2Go, left, histograms 1 and 2), the picture became more heterogenous (Fig. 2Go, left, histograms 3–5). The biphasic MHC class II I-Ab distribution argues for the presence of only a small MHC class II highly positive population. It has been described that the CD11c-CD11b+ population contains a rather heterogeneous mixture of myeloid cells as well as differentiating myeloblasts similar to those found in the CD11c+CD11b+ population (25). Therefore, one might speculate that the CD11c-{beta}2m-transgenic construct leads to {beta}2m expression and reconstitution of Kb on a small fraction of monocytes/macrophages. Another interpretation could be the presence of myeloid precursors in the CD11c-CD11b+ population that gives rise to cells in the myeloid CD11c+CD11b+ DC fraction (25). These cells could be CD11c dull and start to up-regulate the transgene. These observations were made in all mice examined so far. DCs derived from bone marrow cultures of CD11c-MHCI mice also showed wild-type levels of MHC class I Kb expression as compared with the MHCI+/+ control (data not shown).



View larger version (45K):
[in this window]
[in a new window]
  		FIGURE 2. Lymphoid and myeloid DC in CD11c-MHCI-transgenic mice express wild-type levels of MHC class I Kb in vivo. Spleens of the three different mouse strains were collagenase digested as described in Material and Methods and analyzed by three-color flow cytometry. Data are presented for cells with high forward and side light scatter properties of DC. In the CD11c/CD11b staining (dot plot), gates were set on five subpopulations (gates 1–5), through which the relative expression of MHC class II I-Ab (left, MHC class II) or MHC class I Kb (right, MHC class I) was analyzed. In the histogram overlays, the stainings of MHCI+/+ (dotted line), CD11c-MHCI (bold black line), and MHCI-/- mice (thin black line) are compared.

 
In conclusion, the Kb expression in CD11c-MHCI mice seemed to be restricted to DC of the myeloid and lymphoid lineage and to a minority of CD11c-(dull)CD11b+ cells of the myeloid lineage. In contrast, as found by others (H. Goldstein, unpublished observations) and by us (18, 21), the CD11c promoter did not lead to transgene expression in the majority of myeloid cells or B cells.

Cross-presentation of OVA by DC in RIP-mOVA mice

To generate RIP-mOVA mice in which only DC can activate OT-I cells, bone marrow from CD11c-MHCI mice was transplanted into RIP-mOVA.bm1 mice (CD11c-MHC I->RIP-mOVA.bm1). These recipients express the mutant bm1 of the MHC class I molecule Kb, which cannot present OVA to OT-I cells (17). After introduction of CD11c-MHCI mouse bone marrow, only DC present OVA in a Kb-restricted manner. As controls, we engrafted bone marrow from transgene negative littermates of CD11c-MHCI mice (MHCI-/-->RIP-mOVA.bm1) as well as from C57BL/6 mice (MHCI+/+->RIP-mOVA.bm1). In MHCI-/-->RIP-mOVA.bm1 chimeras, no OVA presentation should occur due to the absence of MHC class I on APC. In MHCI+/+->RIP-mOVA.bm1 chimeras, all bone marrow-derived cells are able to present OVA via Kb.

CFSE labeling allows monitoring of cellular proliferation by detecting the dilution of this fluorescent dye as a consequence of cell division. When CFSE-labeled OT-I cells were injected into CD11c-MHCI->RIP-mOVA.bm1 mice, their division could be detected in renal lymph nodes 2 days after transfer (Fig. 3GoC). This proliferation was comparable to that observed in MHCI+/+->RIP-mOVA.bm1 control mice (Fig. 3GoA), in which all bone marrow-derived cells express Kb. In MHCI-/-->RIP-mOVA.bm1 control mice, which differ from CD11c-MHCI->RIP-mOVA.bm1 mice by the lack of transgenic Kb expression in DC, no proliferation was observed (Fig. 3GoE). Thus, the activation of OT-I cells in CD11c-MHCI->RIP-mOVA.bm1 mice depended on the expression of the transgene. No proliferation was detected in the nondraining inguinal lymph nodes of any experimental mice (Fig. 3Go, B, D, and F), demonstrating that activation of OT-I cells was Ag specific. Consistent with this interpretation, no proliferation was observed in CD11c-MHCI->bm1 mice (data not shown), which express Kb on the same cells as CD11c-MHCI->RIP-mOVA.bm1 mice, but lack the model Ag OVA. To avoid an influence of the OT-I cell number, we used a very high dose of CFSE-labeled OT-I cells. Consequently, the peak of undivided cells is relatively large as compared with the percentage of proliferating cells. Because an equivalent number of OT-I cells were driven into cell division and the number of divisions was identical in both the MHC+/+ and CD11c-MHCI (Fig. 3Go, A and C) draining lymph nodes, we concluded that the CD11c+ DC (Fig. 3GoC) were cross-presenting. The above experiments do not formally exclude the possibility that other bone marrow-derived APC can potentially participate in cross presentation in vivo. A definitive answer to this question would require mice deficient for MHC class I only in DC.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 3. Secreted, exogeneous OVA is cross-presented in the draining lymph nodes by DC of CD11c-MHCI mice and induces Ag-specific proliferation of CD8+ OVA-specific T cells. A total of 4 x 106 OT-I cells were labeled with CFSE and injected i.v. into either B6->RIP-mOVA.bm1 mice (A and B), CD11c-MHCI->RIP-mOVA.bm1 mice (C and D), MHCI-/-->RIP-mOVA.bm1 (D and E). Forty-eight hours later, the renal (A, C, and E) and inguinal (B, D, and F) lymph node cells were analyzed by flow cytometry. Negative littermates did not induce proliferation of OT-I cells (data not shown). Histograms were gated on CD8+CFSE+ cells. These results are representative of two experiments with three mice per each group.

 
The question of whether lymphoid or myeloid DC are responsible for cross-presentation cannot be answered in our experimental system because all CD11c+ DC expressed the transgene. Thus, the different stimulatory abilities of these subtypes of CD11c+ DCs could not be distinguished. For the same reason, we could not differentiate between DCs at different stages of maturation, which also have been suggested to induce different outcomes of T cell activation (26). Nevertheless, our results demonstrate that DC are sufficient to cross-present in vivo and do correlate with in vitro findings where DC have been described to be much more efficient in cross-presentation than macrophages (9, 16) or B cells (15).

Furthermore, they provide clear in vivo evidence for the hypothesis that dendritic cells are responsible for cross-presentation of self-Ags (11). The in vivo demonstration of this assumption, as achieved in the present study, suggests that the reported cross-tolerance by deletion of autoreactive CD8 T cells (5, 27), could also be induced by DC. If true, DC would represent not only central initiators of immunity, but also of tolerance.


   Footnotes
 
1 C.K. is supported by a Heisenberg Fellowship and a research grant from the Deutsche Forschungsgemeinschaft (Grant Ku1063/2-1) and by research group grant of the German land Nordrhein-Westfalen. T.B. was supported by a Heisenberg Fellowship from the Deutsche Forschungsgemeinschaft (Grant Br 1889/1-1), a collaborative grant from the Jenner Institute for Vaccine Research, and the Deutsche Forschungsgemeinschaft Sonderforschungsbereich 364. Back

2 Address correspondence and reprint requests to Dr. Christian Kurts, Department of Nephrology and Immunology, University of Aachen, 52074 Aachen, Germany. Back

3 Address correspondence and reprint requests to Dr. Thomas Brocker, Institute for Immunology, Ludwig-Maximilians-Universität München, 80336 München, Goethestrasse 31, Germany. Back

4 Abbreviations used in this paper: DC, dendritic cell; RIP, rat insulin promoter; mOVA, membrane-bound form of OVA; {beta}2m, {beta}2-microglobulin; CD11c-class I mice, mice expressing {beta}2m, and thus MHC class I under the influence of the CD11c promoter on dendritic cells; OT-I cells, transgenic OVA-specific class I-restricted CD8+ T cells. Back

Received for publication October 20, 2000. Accepted for publication November 30, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Bevan, M. J.. 1987. Antigen recognition: class discrimination in the world of immunology. Nature 325:192.[Medline]
  2. Germain, R. N., D. H. Margulies. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403.[Medline]
  3. Rock, K. L.. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today 17:131.[Medline]
  4. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.[Abstract/Free Full Text]
  5. Kurts, C., H. Kosaka, F. R. Carbone, J. F. Miller, W. R. Heath. 1997. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J. Exp. Med. 186:239.[Abstract/Free Full Text]
  6. Yewdell, J. W., C. C. Norbury, J. R. Bennink. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1.[Medline]
  7. Kurts, C., J. F. Miller, R. M. Subramaniam, F. R. Carbone, W. R. Heath. 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188:409.[Abstract/Free Full Text]
  8. Sigal, L. J., S. Crotty, R. Andino, K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 298:77.
  9. Albert, M. L., B. Sauter, N. Bhardwaj. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86.[Medline]
  10. Yrlid, U., M. J. Wick. 2000. Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells. J. Exp. Med. 191:613.[Abstract/Free Full Text]
  11. Steinman, R. M., S. Turley, I. Mellman, K. Inaba. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191:411.[Free Full Text]
  12. Ke, Y., J. A. Kapp. 1996. Exogenous antigens gain access to the major histocompatibility complex class I processing pathway in B cells by receptor-mediated uptake. J. Exp. Med. 184:1179.[Abstract/Free Full Text]
  13. Norbury, C. C., L. J. Hewlett, A. R. Prescott, N. Shastri, C. Watts. 1995. Class I MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3:783.[Medline]
  14. Norbury, C. C., B. J. Chambers, A. R. Prescott, H. G. Ljunggren, C. Watts. 1997. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27:280.[Medline]
  15. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, S. Amigorena. 1999. Fc{gamma} receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371.[Abstract/Free Full Text]
  16. Rodriguez, A., A. Regnault, M. Kleijmeer, P. Ricciardi-Castagnoli, S. Amigorena. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:362.[Medline]
  17. Kurts, C., W. R. Heath, F. R. Carbone, J. Allison, J. F. Miller, H. Kosaka. 1996. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 184:923.[Abstract/Free Full Text]
  18. Brocker, T., M. Riedinger, K. Karjalainen. 1997. Targeted Expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J. Exp. Med. 185:541.[Abstract/Free Full Text]
  19. Koller, B. H., O. Smithies. 1989. Inactivating the {beta}2-microglobulin locus in mouse embryonic stem cells by homologous recombination. Proc. Natl. Acad. Sci. USA 86:8932.[Abstract/Free Full Text]
  20. Brocker, T.. 1997. Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J. Exp. Med. 186:1223.[Abstract/Free Full Text]
  21. Brocker, T., A. Gulbranson-Judge, S. Flynn, M. Riedinger, C. Raykundalia, P. Lane. 1999. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur. J. Immunol. 29:1610.[Medline]
  22. Kleindienst, P., I. Chretien, T. Winkler, T. Brocker. 2000. Functional comparison of thymic B cells and dendritic cells in vivo. Blood 95:2610.[Abstract/Free Full Text]
  23. Vremec, D., M. Zorbas, R. Scollay, D. J. Saunders, C. F. Ardavin, L. Wu, K. Shortman. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176:47.[Abstract/Free Full Text]
  24. Vremec, D., K. Shortman. 1997. Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J. Immunol. 159:565.[Abstract]
  25. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953.[Abstract/Free Full Text]
  26. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.[Medline]
  27. Morgan, D. J., H. T. Kreuwel, L. A. Sherman. 1999. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J. Immunol. 163:723.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. Dresch, S. L. Edelmann, P. Marconi, and T. Brocker
Lentiviral-Mediated Transcriptional Targeting of Dendritic Cells for Induction of T Cell Tolerance In Vivo
J. Immunol., October 1, 2008; 181(7): 4495 - 4506.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. von Stebut
Phagocytic neutrophils cross-present antigen
Blood, October 15, 2007; 110(8): 2782 - 2782.
[Full Text] [PDF]

Home page
 J. Exp. Med.Home page
A. Sapoznikov, J. A.A. Fischer, T. Zaft, R. Krauthgamer, A. Dzionek, and S. Jung
Organ-dependent in vivo priming of naive CD4+,but not CD8+,T cells by plasmacytoid dendritic cells
J. Exp. Med., August 6, 2007; 204(8): 1923 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. T. Hagymasi, A. M. Slaiby, M. A. Mihalyo, H. Z. Qui, D. J. Zammit, L. Lefrancois, and A. J. Adler
Steady State Dendritic Cells Present Parenchymal Self-Antigen and Contribute to, but Are Not Essential for, Tolerization of Naive and Th1 Effector CD4 Cells
J. Immunol., August 1, 2007; 179(3): 1524 - 1531.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Werner-Klein, C. Dresch, P. Marconi, and T. Brocker
Transcriptional Targeting of B Cells for Induction of Peripheral CD8 T Cell Tolerance
J. Immunol., June 15, 2007; 178(12): 7738 - 7746.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. de Jersey, S. L. Snelgrove, S. E. Palmer, S. A. Teteris, A. Mullbacher, J. F. A. P. Miller, and R. M. Slattery
beta Cells cannot directly prime diabetogenic CD8 T cells in nonobese diabetic mice
PNAS, January 23, 2007; 104(4): 1295 - 1300.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Reibke, N. Garbi, R. Ganss, G. J. Hammerling, B. Arnold, and T. Oelert
CD8+ regulatory T cells generated by neonatal recognition of peripheral self-antigen
PNAS, October 10, 2006; 103(41): 15142 - 15147.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Seamons, A. Perchellet, and J. Goverman
Endogenous Myelin Basic Protein Is Presented in the Periphery by Both Dendritic Cells and Resting B Cells with Different Functional Consequences
J. Immunol., August 15, 2006; 177(4): 2097 - 2106.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Lauterbach, A. Gruber, C. Ried, C. Cheminay, and T. Brocker
Insufficient APC Capacities of Dendritic Cells in Gene Gun-Mediated DNA Vaccination.
J. Immunol., April 15, 2006; 176(8): 4600 - 4607.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Le Bon, V. Durand, E. Kamphuis, C. Thompson, S. Bulfone-Paus, C. Rossmann, U. Kalinke, and D. F. Tough
Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming.
J. Immunol., April 15, 2006; 176(8): 4682 - 4689.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. Dumortier, G. J. D. van Mierlo, D. Egan, W. van Ewijk, R. E. M. Toes, R. Offringa, and C. J. M. Melief
Antigen Presentation by an Immature Myeloid Dendritic Cell Line Does Not Cause CTL Deletion In Vivo, but Generates CD8+ Central Memory-Like T Cells That Can Be Rescued for Full Effector Function
J. Immunol., July 15, 2005; 175(2): 855 - 863.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Gruber and T. Brocker
MHC Class I-Positive Dendritic Cells (DC) Control CD8 T Cell Homeostasis In Vivo: T Cell Lymphopenia as a Prerequisite for DC-Mediated Homeostatic Proliferation of Naive CD8 T Cells
J. Immunol., July 1, 2005; 175(1): 201 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Krebs, E. Scandella, B. Odermatt, and B. Ludewig
Rapid Functional Exhaustion and Deletion of CTL following Immunization with Recombinant Adenovirus
J. Immunol., April 15, 2005; 174(8): 4559 - 4566.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
F. Boisgerault, P. Rueda, C. M. Sun, S. Hervas-Stubbs, M. Rojas, and C. Leclerc
Cross-Priming of T Cell Responses by Synthetic Microspheres Carrying a CD8+ T Cell Epitope Requires an Adjuvant Signal
J. Immunol., March 15, 2005; 174(6): 3432 - 3439.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Y.-G. Chen, C.-M. Choisy-Rossi, T. M. Holl, H. D. Chapman, G. S. Besra, S. A. Porcelli, D. J. Shaffer, D. Roopenian, S. B. Wilson, and D. V. Serreze
Activated NKT Cells Inhibit Autoimmune Diabetes through Tolerogenic Recruitment of Dendritic Cells to Pancreatic Lymph Nodes
J. Immunol., February 1, 2005; 174(3): 1196 - 1204.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. A. Cannarile, N. Decanis, J. P. M. van Meerwijk, and T. Brocker
The Role of Dendritic Cells in Selection of Classical and Nonclassical CD8+ T Cells In Vivo
J. Immunol., October 15, 2004; 173(8): 4799 - 4805.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. A. Quezada, B. Fuller, L. Z. Jarvinen, M. Gonzalez, B. R. Blazar, A. Y. Rudensky, T. B. Strom, and R. J. Noelle
Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation
Blood, September 1, 2003; 102(5): 1920 - 1926.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hayashi, T. Hideshima, M. Akiyama, N. Raje, P. Richardson, D. Chauhan, and K. C. Anderson
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes
Blood, August 15, 2003; 102(4): 1435 - 1442.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. E. Hamilton-Williams, S. E. Palmer, B. Charlton, and R. M. Slattery
Beta cell MHC class I is a late requirement for diabetes
PNAS, May 27, 2003; 100(11): 6688 - 6693.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Heit, T. Maurer, H. Hochrein, S. Bauer, K. M. Huster, D. H. Busch, and H. Wagner
Cutting Edge: Toll-Like Receptor 9 Expression Is Not Required for CpG DNA-Aided Cross-Presentation of DNA-Conjugated Antigens but Essential for Cross-Priming of CD8 T Cells
J. Immunol., March 15, 2003; 170(6): 2802 - 2805.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
P. Kleindienst and T. Brocker
Endogenous Dendritic Cells Are Required for Amplification of T Cell Responses Induced by Dendritic Cell Vaccines In Vivo
J. Immunol., March 15, 2003; 170(6): 2817 - 2823.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. N. Mueller, C. M. Jones, W. Chen, Y. Kawaoka, M. R. Castrucci, W. R. Heath, and F. R. Carbone
The Early Expression of Glycoprotein B from Herpes Simplex Virus Can Be Detected by Antigen-Specific CD8+ T Cells
J. Virol., February 15, 2003; 77(4): 2445 - 2451.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
L. Bonifaz, D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig, and R. M. Steinman
Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance
J. Exp. Med., December 16, 2002; 196(12): 1627 - 1638.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
E. Mougneau, S. Hugues, and N. Glaichenhaus
Antigen Presentation by Dendritic Cells In Vivo
J. Exp. Med., October 21, 2002; 196(8): 1013 - 1016.
[Full Text] [PDF]

Home page
 J. Exp. Med.Home page
C. Scheinecker, R. McHugh, E. M. Shevach, and R. N. Germain
Constitutive Presentation of a Natural Tissue Autoantigen Exclusively by Dendritic Cells in the Draining Lymph Node
J. Exp. Med., October 21, 2002; 196(8): 1079 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
K. Liu, T. Iyoda, M. Saternus, Y. Kimura, K. Inaba, and R. M. Steinman
Immune Tolerance After Delivery of Dying Cells to Dendritic Cells In Situ
J. Exp. Med., October 21, 2002; 196(8): 1091 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
G. T. Belz, G. M.N. Behrens, C. M. Smith, J. F.A.P. Miller, C. Jones, K. Lejon, C. G. Fathman, S. N. Mueller, K. Shortman, F. R. Carbone, et al.
The CD8{alpha}+ Dendritic Cell Is Responsible for Inducing Peripheral Self-Tolerance to Tissue-associated Antigens
J. Exp. Med., October 21, 2002; 196(8): 1099 - 1104.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
G. M. Davey, C. Kurts, J. F.A.P. Miller, P. Bouillet, A. Strasser, A. G. Brooks, F. R. Carbone, and W. R. Heath
Peripheral Deletion of Autoreactive CD8 T Cells by Cross Presentation of Self-Antigen Occurs by a Bcl-2-inhibitable Pathway Mediated by Bim
J. Exp. Med., October 7, 2002; 196(7): 947 - 955.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
J. Hernandez, S. Aung, K. Marquardt, and L. A. Sherman
Uncoupling of Proliferative Potential and Gain of Effector Function by CD8+ T Cells Responding to Self-Antigens
J. Exp. Med., August 5, 2002; 196(3): 323 - 333.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Schulz, D. J. Pennington, K. Hodivala-Dilke, M. Febbraio, and C. Reis e Sousa
CD36 or {alpha}v{beta}3 and {alpha}v{beta}5 Integrins Are Not Essential for MHC Class I Cross-Presentation of Cell-Associated Antigen by CD8{alpha}+ Murine Dendritic Cells
J. Immunol., June 15, 2002; 168(12): 6057 - 6065.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. T. Belz, D. Vremec, M. Febbraio, L. Corcoran, K. Shortman, F. R. Carbone, and W. R. Heath
CD36 Is Differentially Expressed by CD8+ Splenic Dendritic Cells But Is Not Required for Cross-Presentation In Vivo
J. Immunol., June 15, 2002; 168(12): 6066 - 6070.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. S. Schmidt and M. F. Mescher
Peptide Antigen Priming of Naive, But Not Memory, CD8 T Cells Requires a Third Signal That Can Be Provided by IL-12
J. Immunol., June 1, 2002; 168(11): 5521 - 5529.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
S. Amigorena
Fc{gamma} Receptors and Cross-Presentation in Dendritic Cells
J. Exp. Med., January 7, 2002; 195(1): F1 - F3.
[Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. F. Lipscomb and B. J. Masten
Dendritic Cells: Immune Regulators in Health and Disease
Physiol Rev,